课题基金 / 基金详情

Ultra Low Latency Video Streaming Platform

Ultra Low Latency Video Streaming Platform
超低延迟视频流平台
批准号:
60930
负责人:
金额:
$9.3万
依托单位:
依托单位国家:
英国
项目类别:
Feasibility Studies
财政年份:
2020
资助国家:
英国
项目状态:
已结题
起止时间:
2020 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
8by 8正在开发一个网络平台,该平台能够以超低延迟(不到3秒)向观众传输高质量的视频。现有的用户友好型服务,如YouTubeLive,可以高质量运行,但延迟很高。此外,用户将其输出品牌化的能力有限。实时会议以低延迟运行,但质量较差。现有的超低延迟解决方案需要大量的硬件和软件配置,并且可能需要现场存在。8by 8的视频平台旨在通过与云提供商和硬件制造商合作来填补市场上的这一空白,以帮助为非技术用户带来超低延迟。这将有助于解决用户因新冠肺炎而面临的紧迫需求,并使更多工作能够远程进行-减少对环境的影响。他们的在线视频管理和分发工具被世界上一些最大的联赛用于协助比赛官员的培训和评估,上诉流程和决策沟通。8by 8有机会在众多不同的环境中与最终用户进行beta测试。通过探索这些测试用例,这将允许进一步开发,以确保满足用户的直接需求。
英文摘要
8by8 are developing a web platform which enables the streaming of high-quality video, to viewers at ultra-low latency (less than 3 seconds).Existing user-friendly services such as YouTubeLive run at a high quality, but with a high latency. Additionally, the ability for users to brand their output is limited. Real-time conferencing runs at low latency but with poorer quality. Existing ultra low latency solutions require significant hardware and software configuration, and may require an on site presence.8by8's video platform aims to fill this gap in the market by working with cloud providers and hardware manufacturers to help bring ultra low latency to non technical users. This will help address the immediate needs users are facing as a result of Covid-19, as well as enabling more jobs to be carried out remotely - reducing environmental impact.8by8 is a sports technology company. Their online video management and distribution tools are used by some of the largest leagues in the world to assist with the training and assessment of match officials, appeal processes and communication of decisions.8by8 has the opportunity to run beta tests with end users in a multitude of different environments. By exploring these test cases this will allow for further development to ensure that the immediate user needs are met.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
骨髓微环境中正常造血干/祖细胞新亚群IL7Rα(-)LSK(low)细胞延缓急性髓系白血病进程的作用及机制研究
MSCEN聚集体抑制CD127low单核细胞铜死亡治疗SLE 的机制研究
  • 批准号:
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2024
  • 负责人:
    耿林玉
  • 依托单位:
新型PDL1+CXCR2low中性粒细胞在脉络膜新生血管中的作用及机制研究
  • 批准号:
    82271095
  • 项目类别:
    面上项目
  • 资助金额:
    56万元
  • 批准年份:
    2022
  • 负责人:
    柳夏林
  • 依托单位:
CD9+CD55low脂肪前体细胞介导高脂诱导脂肪组织炎症和2型糖尿病的作用和机制研究
  • 批准号:
    82270883
  • 项目类别:
    面上项目
  • 资助金额:
    52万元
  • 批准年份:
    2022
  • 负责人:
    毕艳
  • 依托单位: